{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:47:22Z","timestamp":1762300042658,"version":"3.41.2"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors are promising agents for anticancer therapy. But despite their high efficacy in the treatment of solid tumors, there is still a problem with immune-related adverse events, especially cardiovascular complications with a very high mortality rate. Myocarditis or ischemic heart disease progression is not the only possible cause of cardiovascular death in patients treated with checkpoint inhibitors. We report a case of a patient with mucinous carcinoma of the lung, with a previous history of hypertension and moderate left ventricular dysfunction. The patient was prescribed atezolizumab, but the first atezolizumab infusion resulted in the patient cardiovascular death. Postmortem histopathological evaluation of myocardium revealed several possible reasons for hemodynamic instability: tumor embolism of the coronary arteries, micrometastases of mucinous carcinoma in the myocardium, and myocarditis diagnosed by both Dallas and immunohistochemistry criteria. In addition, testing for expression of PD-L1 detected the high levels of membranous and cytoplasmic PD-L1 protein even in the myocardium area free from tumor cells. The present clinical case demonstrates a problem of cardiovascular death in patients treated with checkpoint inhibitors and actualizes the need for future research of potential risk factors for cardiovascular complications.<\/jats:p>","DOI":"10.3389\/fimmu.2022.871542","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T09:32:10Z","timestamp":1648719130000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Multiple Causes of Cardiac Death After the First Infusion of Atezolizumab: Histopathological and Immunohistochemical Findings"],"prefix":"10.3389","volume":"13","author":[{"given":"Ekaterina","family":"Kushnareva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizaveta","family":"Artemeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana","family":"Shuginova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Kushnarev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Simakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fedor","family":"Moiseenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Moiseeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased Reporting of Fatal Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current State of Knowledge on Aetiology, Diagnosis, Management, and Therapy of Myocarditis: A Position Statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.11.16","article-title":"Membrane PD-L1 Expression and Soluble PD-L1 Plasma Levels in Idiopathic Pulmonary Fibrosis-a Pilot Study","volume":"10","author":"Jovanovic","year":"2018","journal-title":"J Thorac Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1007468","article-title":"Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter Pylori Infection","volume":"15","author":"Holokai","year":"2019","journal-title":"PloS Pathog"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0124059","article-title":"Upregulation of Programmed Death-1 and its Ligand in Cardiac Injury Models: Interaction With GADD153","volume":"10","author":"Baban","year":"2015","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.4.2513","article-title":"Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice","volume":"181","author":"Lucas","year":"2008","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.709360","article-title":"Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8+ T-Cell-Mediated Injury in the Heart","volume":"116","author":"Grabie","year":"2007","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.15829\/1560-4071-2020-3910","article-title":"Immune Checkpoint Inhibitor Myocarditis: A Systematic Case Study","volume":"25","author":"Kushnareva","year":"2020","journal-title":"Russian J Cardiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12113480","article-title":"Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting With Immune Checkpoint Inhibitors: A Vigibase Study","volume":"12","author":"Noseda","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.02.016","article-title":"Cardiovascular Health and Outcomes in Cancer Pa- Tients Receiving Immune Checkpoint Inhibitors","volume":"125","author":"Oren","year":"2020","journal-title":"Am J Cardiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.759972","article-title":"Myocardial PD-L1 Expression in Patients With Ischemic and Non-Ischemic Heart Failure","volume":"8","author":"Kushnareva","year":"2022","journal-title":"Front Cardiovasc Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.871542\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T09:32:13Z","timestamp":1648719133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.871542\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2022.871542"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.871542","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"article-number":"871542"}}